Effect of fibrinolytic therapy on ST-elevation myocardial infarction clinical outcomes during the COVID-19 pandemic: A systematic review and meta-analysis

Figure 1 PRISMA chart displaying the process of search to study selection.

Figure 2 No evidence of publication bias. A: When studies have been divided based on the incidence of fibrinolysis; B: When studies have been divided based on the income status of countries. HIC: High-income countries; LMIC: Low- and middle-income countries.

Figure 3 Increased incidence. A: Fibrinolysis during the pandemic period; B: Fibrinolysis in low-and middle-income countries as compared to high-income countries. HIC: High-income countries; LMIC: Low- and middle-income countries.

Figure 4 No association between all-cause mortality rate and the incidence of fibrinolysis.

Figure 5 Increased all cause-mortality rate in low-and middle-income countries compared to high-income countries. HIC: High-income countries; LMIC: Low- and middle-income countries.

Figure 6 Meta-regression plot. A: The significant direct relationship between hyperlipidemia and the risk for all-cause of mortality; B: Meta-regression plot displaying the direct relationship between hypertension and the risk for all-cause of mortality. HLD: Hyperlipidemia; HTN: Hypertension.